Journal
ALZHEIMERS & DEMENTIA-TRANSLATIONAL RESEARCH & CLINICAL INTERVENTIONS
Volume 7, Issue 1, Pages -Publisher
WILEY
DOI: 10.1002/trc2.12181
Keywords
Alzheimer's disease; clinical meaningfulness; cognitive decline; dementia; Research Roundtable; treatment
Categories
Funding
- NIH/NIA [K23AG061253]
- Larry L. Hillblom Foundation [2018-A-025-FEL]
Ask authors/readers for more resources
The Research Roundtable discussed the lack of consensus on defining clinical meaningfulness at different stages. Participants engaged in discussions about various approaches to defining clinical meaningfulness from different perspectives.
Demonstrating that treatments are clinically meaningful across the Alzheimer's disease (AD) continuum is critical for meeting our goals of accelerating a cure by 2025. While this topic has been a focus of several Alzheimer's Association Research Roundtable (AARR) meetings, there remains no consensus as to what constitutes a clinically meaningful outcome in the eyes of patients, clinicians, care partners, policymakers, payers, and regulatory bodies. Furthermore, the field has not come to agreement as to what constitutes a clinically meaningful treatment effect at each stage of disease severity. The AARR meeting on November 19-20, 2019, reviewed current approaches to defining clinical meaningfulness from various perspectives including those of patients and care partners, clinicians, regulators, health economists, and public policymakers. Participants discussed approaches that may confer clinical relevance at each stage of the disease continuum and fostered discussion about what should guide us in the future.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available